Monia Brett P, Chief Executive Officer of Ionis Pharmaceuticals (IONS), has demonstrated a clear selling bias in recent insider transactions, with no buys and 12 sales recorded since January 2026. The executive’s total sell activity amounts to $41.3 million across 50 transactions, dwarfing the $18.2 million in buys—a pattern that has intensified this year. Notably, March 2026 saw concentrated disposals, including a $8.85 million sale on March 9 and two transactions totaling $2.59 million the following day, alongside multiple smaller sales and derivative transactions marked as "M" (exercise of derivative security). Earlier in the year, Brett executed significant sales, including a $5.21 million transaction on January 30 and a $3.29 million sale on January 16.
The activity suggests a sustained reduction in Brett’s position in IONS, with the majority of sales occurring in early 2026. While some transactions appear routine—such as tax-related sales or option exercises—the scale and frequency of disposals indicate a deliberate unwind. The lack of any offsetting buys during this period reinforces the trend. Historical data shows similar selling patterns in late 2025, including a $7.67 million sale on September 3, suggesting this disposition has been ongoing for months. All transactions involve IONS, reflecting Brett’s exclusive focus on this single holding in recent filings. The absence of purchases since at least September 2025 underscores a one-directional trading approach.
AI-assisted summary